All News

Richard Conway Tweet
RichardPAConway

After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

k dao Tweet
KDAO2011
When you counsel patients w/RA, do you warn them that during times of dz flare, their ability to drive may be affected? ...maybe you should based on Abstr#0198 #ACR20 @rheumnow
David Liew Tweet
drdavidliew
Nice insights into RA-ILD from @jeffsparks: - assoc (in Medicare): male, smoker, asthma/COPD, b/tsDMARDs, steroids - mortality risk? Yes, esp resp (sdHR 4.4), cancer - ACPA/lung inflamm related to RA-ILD? Yes, esp anti-filaggrin (aOR 3.08/log unit) #ACR20 ABST0489/0490 @RheumNow https://t.co/DGkNNPOcbd
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
Be sure to check this session with @CCalabreseDO and Dr. Gordon Lam on the role of IL6 in inflammation, RA, and CRS at 2 pm EST today! #ACR20 @RheumNow https://t.co/c4oX1tNeId
Janet Pope Tweet
Janetbirdope
Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX better than D/C etanercept in controlled RA. ETN alone =ETN+MTX. I vote to d/c the Rx that failed or by pt preference! Abstr#939 @RheumNow #ACR20 https://t.co/l9TNM3Gt0e
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Richard Conway Tweet
RichardPAConway
Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. @rheumnow #ACR20 Abstr#939 #ACRbest https://t.co/wpAtBHJYUF
sheila Tweet
RHEUMarampa
Important things to take note of re: HBV reactivation (risk stratification and RR) when we consider therapies for our RA pts. 👇 @RheumNow #ACR20 #MedTwitter https://t.co/ZJfnZHpmfw
Janet Pope Tweet
Janetbirdope

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

sheila Tweet
RHEUMarampa
Liver damage is NOT an extra-articular manifestation of RA BUT the ff'g factors are associated with liver disease in RA & can complicate management👇@RheumNow #ACR20 https://t.co/RqL69iVJpC
sheila Tweet
RHEUMarampa
What is refractory RA? Inability to reach #T2T goals of remission or at least LDA despite various changes of tx. "We should aim at best care for the tx of refractory RA"-Prof.Josef Smolen @RheumNow #ACR20 https://t.co/7Wxjd5t3Oi
sheila Tweet
RHEUMarampa
Nintedanib for RA-ILD? In the INBUILD Trial, pts on Nintedanib did better than PBO, efficacy similar among autoimmune ILDs including RA. @RheumNow #ACR20 @joanbathon https://t.co/I4AJlemIhD
sheila Tweet
RHEUMarampa

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

Janet Pope Tweet
Janetbirdope
ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s
sheila Tweet
RHEUMarampa
In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX
sheila Tweet
RHEUMarampa
Anti-PAD Abs seen in 1/3 of pts at-risk for RA and 1/3 of pts w/ CSA. Implications? Possible predictive value of anti-PAD Abs in RA dse progression? @RheumNow #ACR20 abs0761 #ACRbest https://t.co/VpkjwU2YZm
×